FDA Panel Backs Adding Peptides to Compounding List, Overruling Agency Scientists
The Food and Drug Administration's (FDA) Pharmacy Compounding Advisory Committee (PCAC) voted on Thursday to include peptides on the list of substances that compounding pharmacies are permitted to create. This decision goes against the recommendations of agency scientists, who had raised concerns about the lack of demonstrated benefits for these peptides. During the meeting, the committee considered public comments and presentations from FDA staff regarding specific peptides, including BPC-157, KPV, TB-500, and MOTS-C. The vote signifies a divergence between the advisory committee and the FDA's internal scientific assessments concerning the therapeutic value and safety of these compounds for compounding purposes.
The FDA panel's decision to add peptides to the compounding list, despite internal scientific reservations, highlights potential tensions between regulatory oversight and the demand for novel therapeutic agents. This action may reflect market pressures or patient advocacy influencing regulatory pathways. Future considerations should focus on establishing robust evidence frameworks for compounded substances to ensure both innovation and patient safety, particularly as the pharmaceutical landscape evolves with advanced molecular compounds. This event prompts a review of the criteria and processes used for evaluating substances in compounding, aiming for a balance that supports access while upholding rigorous scientific standards.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.